Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice.

Cordony A, Le Reun C, Smala A, Symanowski JT, Watkins J.

Value Health. 2008 Jan-Feb;11(1):4-12. doi: 10.1111/j.1524-4733.2007.00209.x.

2.

Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.

Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, Hill R, McLeod C, Walley T.

Health Technol Assess. 2007 Jan;11(1):1-90. Review.

3.

Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.

Woods B, Paracha N, Scott DA, Thatcher N.

Lung Cancer. 2012 Feb;75(2):261-7. doi: 10.1016/j.lungcan.2011.07.011. Epub 2011 Sep 19.

PMID:
21937141
4.

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.

Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, Dickson R, Tudur Smith C, Davis H, Green J, Pearson M.

Health Technol Assess. 2010 May;14 Suppl 1:47-53. doi: 10.3310/hta14Suppl1/07. Review.

5.

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK; Pemetrexed expanded access program investigators.

J Thorac Oncol. 2006 Jul;1(6):506-12. Erratum in: J Thorac Oncol. 2006 Sep;1(7):621.

6.

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ.

Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11.

PMID:
15824080
7.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
8.

Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.

Green J, Dundar Y, Dodd S, Dickson R, Walley T.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005574. Review.

PMID:
17253564
9.

The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.

Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

J Thorac Oncol. 2006 Jul;1(6):591-601. Review.

10.

Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):212-4.

PMID:
16400741
11.

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.

J Thorac Oncol. 2008 Jul;3(7):756-63. doi: 10.1097/JTO.0b013e31817c73d6.

12.

Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.

Manegold C.

Semin Oncol. 2003 Aug;30(4 Suppl 10):32-6. Review.

PMID:
12917819
13.

Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.

Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M.

Value Health. 2012 Jan;15(1):65-71. doi: 10.1016/j.jval.2011.08.1737. Epub 2011 Oct 22.

14.

Pemetrexed in malignant pleural mesothelioma.

Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R.

Clin Cancer Res. 2005 Feb 1;11(3):982-92.

15.

Pemetrexed for diffuse malignant pleural mesothelioma.

Manegold C, Aisner J.

Semin Oncol. 2002 Apr;29(2 Suppl 5):30-5. Review.

PMID:
12023790
16.

Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.

Budde LS, Hanna NH.

Expert Rev Anticancer Ther. 2004 Jun;4(3):361-8. Review.

PMID:
15161435
17.

The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.

Boons CC, VAN Tulder MW, Burgers JA, Beckeringh JJ, Wagner C, Hugtenburg JG.

Anticancer Res. 2013 Sep;33(9):3553-61. Review.

PMID:
24023280
18.

Pemetrexed-cisplatin combination in mesothelioma.

Reck M, Gatzemeier U.

Expert Rev Anticancer Ther. 2005 Apr;5(2):231-7. Review.

PMID:
15877521
19.

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.

Health Technol Assess. 2010 Oct;14(Suppl. 2):33-9. doi: 10.3310/hta14suppl2/05. Review.

20.

In Australia, patients and government at odds over mesothelioma treatment costs.

Burkitt V.

J Natl Cancer Inst. 2007 Dec 5;99(23):1750-2. Epub 2007 Nov 27. No abstract available.

PMID:
18042927

Supplemental Content

Support Center